Genmab A/S Sponsored ADR (GMAB) vs Moderna, Inc. (MRNA)
- Genmab A/S Sponsored ADR GMAB 50.63 −1.40%
- Moderna, Inc. MRNA 195.12 −2.11%
Genmab A/S Sponsored ADR and Moderna, Inc. are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $79.6B against $31.5B — 2.5× the size. Moderna, Inc. has negative trailing earnings, so its P/E is not meaningful; Genmab A/S Sponsored ADR trades at 43.0×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 19.8% against 13.1%. Genmab A/S Sponsored ADR has the higher net margin (17.0% vs −110.5%) and the higher return on invested capital (6.89% vs −35.1%). Across the 18 metrics below, Genmab A/S Sponsored ADR leads on 11 and Moderna, Inc. on 7.
Valuation
Profitability
| Metric | GMAB | MRNA | Biotechnology median |
|---|---|---|---|
| Gross margin | 92.60% | 28.00% | 70.18% |
| Operating margin | 24.30% | (116.04%) | 0.00% |
| Net margin | 16.97% | (110.46%) | 0.00% |
| Free cash flow margin | (148.32%) | (80.95%) | 0.00% |
| Return on equity | 12.07% | (34.50%) | (51.58%) |
| Return on assets | 7.31% | (21.79%) | (45.91%) |
| Return on invested capital | 6.89% | (35.12%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack